Benutzerspezifische Werkzeuge

Andere Leukämien/MDS

Napoleon-Register

National acute promyelocytic leukemia (APL) observational study - NAPOLEON-Registry of the german AML-Intergroup


Hauptprüfer Dresden:
Tel: +49 351 4583192


SAL-MPN-Register

MPN-Register und Biomaterialbank der Studienallianz Leukämien (SAL)

MPN-Register und Biomaterialbank der Studienallianz Leukämien (SAL)


Hauptprüfer Dresden: Prof. Dr. Uwe Platzbecker


Dacota

A Randomized Phase III study of Decitabine (DAC) with or without Hydroxyurea (HY) versus HY in patients with advanced proliferative Chronic Myelomonocytic Leukemia (CMML)


Studienwebseite öffnen
Hauptprüfer Dresden: Prof. Dr. Uwe Platzbecker


GS-US-352-1214

A Phase 3, Randomized Study to Evaluate the Efficacy of Momelotinib versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post- essential Thrombocythemia Myelofibrosis who were treated with Ruxolitinib


Studienwebseite öffnen
Hauptprüfer Dresden:
Studiensekretariat: Una Wendler Tel: +49 351 4589463


EUROPE

PROSPECTIVE VALIDATION OF A PREDICTIVE MODEL OF RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IPSS LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME (MDS) AND THROMBOCYTOPENIA - THE EUROPE-TRIAL


Studienwebseite öffnen
Hauptprüfer Dresden:
Tel: 4969


CD34+FISH+SNP-study

Sequential comprehensive genetic analysis of circulating CD34+ cells in MDS Sequentielle umfassende genetische Analyse zirkulierender CD34+ Zellen bei MDS (CD34+FISH+SNP-Studie)


Hauptprüfer Dresden:
Tel: 5197


Ruxo-BEAT

Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia


Studienwebseite öffnen
Hauptprüfer Dresden:
Tel: 2633


APOLLO

A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLine-based chemotherapy (AIDA regimen) for patients with newLy diagnosed, high-risk acute prOmyelocytic leukemia


Hauptprüfer Dresden:
Tel: 5197


CC-5013-MDS-010

A prospective non-interventional post-authoriszation safety study (PASS), designed as as disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q)


Studienwebseite öffnen
Hauptprüfer Dresden:
Tel: 2633


Medalist ACE-536-MDS-001

A Phase 3, Double-Blind, Randomized Study To Compare The Efficacy And Safeta of Luspatercept (ACE 536) versus Placebo For The Treatment Of Anemia Due To IPSS-R Very Low, Low, Or Intermediate Risk Myolodysplastic Syndomes In Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions


Hauptprüfer Dresden:
Studiensekretariat: Tel: +49 351 458 19463


Onconova 04-30

A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent


Studienwebseite öffnen
Hauptprüfer Dresden:
Studiensekretariat: Tel: +49 351 458 19463


DasaHIT

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line).(Dasatinib Holiday for Improved Tolerability)


Hauptprüfer Dresden: PD Dr. Rainer Ordemann
Studiensekretariat: Gina Lehmann Tel: +49 351 4583273


SINTRA-REV

Multicenter, Randomized, Double-Blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion


Hauptprüfer Dresden:
Tel: 2633


MEDI 4736-MDS-001

A Randomized, Multicenter, Open- Label, Phase 2 Study Evaluating The Efficacy And Safety Of Azacitidine Subcutanous In Combination With Durvalumab (MEDI 4736) In Previously Untreated Subjects With Higher- Risk Myelodysplastic Syndromes (MDS) Or In Eldery (> 65 Years) Acute Myeloid LeuKemia (AML) Subjects Not Eligible For Hematopoietic Stem Cell Transplantation (HSCT)


Hauptprüfer Dresden: Dr. Katja Sockel
Studiensekretariat: Tel: +49 351 458 12091


Astellas2215

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation


Studienwebseite öffnen
Hauptprüfer Dresden: PD Dr. med. Christoph Röllig
Studiensekretariat: Susann Hollstein Tel: +49 351 4584535


SAMBA

Single Agent JNJ-56022473 in MDS and AML Patients failing hypomethylating agent based therapy


Hauptprüfer Dresden:
Tel: 5197


MOR208C205

A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Bruton´s Tyrosine Kinase (BTK) Inhibitor


Hauptprüfer Dresden:
Studiensekretariat: Susann Hollstein Tel: +49 351 4584535


H3 Biomedicine

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia.


Studienwebseite öffnen
Hauptprüfer Dresden: Prof. Dr. Uwe Platzbecker
Studiensekretariat: Tel: 0351/45817520


CLL13

A PHASE 3 MULTICENTER, RANDOMIZED, PROSPECTIVE, OPEN-LABEL TRIAL OF STANDARD CHEMOIMMUNOTHERAPY (FCR/BR) VERSUS RITUXIMAB PLUS VENETOCLAX (RVe) VERSUS OBINUTUZUMAB (GA101) PLUS VENETOCLAX (GVe) VERSUS OBINUTUZUMAB PLUS IBRUTINIB PLUS VENETOCLAX (GIVE) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17p) OR TP53 MUTATION


Studienwebseite öffnen
Hauptprüfer Dresden:
Studiensekretariat: Susann Hollstein Tel: +49 351 4584535


BoHemE Study

A Prospective Longitudinal Cohort Study to Investigate the Interactions of Bone and Hematopoiesis in the Elderly


Studienwebseite öffnen
Hauptprüfer Dresden: Dr. Katja Sockel
Studiensekretariat: Lisa Deutsch Tel: 3089


HAMLET

A randomized controlled trial comparing outcome after hematopoietic cell transplantation from a partially matched unrelated versus haploidentical donor


Hauptprüfer Dresden: PD Dr. Johannes Schetelig
Studiensekretariat: Sandra König Tel: +49 351 4587572


FGCL-4592-082

A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustad (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB)


Studienwebseite öffnen
Hauptprüfer Dresden:
Tel: +49 351 4582046


GEM333

A Multicenter, Open-label, Dose-escalating, Phase I Trial with GEM333, a CD33 Targeted Bispecific Anti-body Engaging T-cells, in Relapsed or Refractory acute Myeloid Leukemia.


Studienwebseite öffnen
Hauptprüfer Dresden:
Studiensekretariat: Tel: 0351/45817566


Abbvie M15-531

A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS).

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in subjects with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.


Studienwebseite öffnen
Hauptprüfer Dresden: Prof. Dr. Uwe Platzbecker
Studiensekretariat: Tel: 0351/45817520


Pevonedistat-3001

A Phase 3, Randomized, Controlled,Open-label,Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia


Hauptprüfer Dresden: Dr. Katja Sockel
Tel: 12091


CLL2-BCG

A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101 maintenance in CLL patients (CLL2-BCG protocol)


Hauptprüfer Dresden:
Studiensekretariat: Susann Hollstein Tel: +49 351 4584535


BERGAMO

Phase 2-Studie zur Untersuchung der Wirksamkeit und Sicherheit von Bemcentinib bei MDS- und AML-Patienten, die kein Ansprechen auf Standardtherapien zeigen


Hauptprüfer Dresden: Dr. Katja Sockel
Studiensekretariat: Lisa Deutsch Tel: 3089


Novartis CPDR001X2105

Phase 1b, multi-arm, open-label study of PDR001 and/or MBG453 in combination with decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome.


Studienwebseite öffnen
Hauptprüfer Dresden:
Studiensekretariat: Tel: 0351/45819648


Boehringer-Ingelheim 1315.7

A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes.


Studienwebseite öffnen
Hauptprüfer Dresden:
Studiensekretariat: Tel: 0351/45811848


Faszienprogramm nach alloSZT

Faszienprogramm nach alloSZT


Hauptprüfer Dresden:
Studiensekretariat: Tel: +49 351-458 6503